CD33 Siglec Receptor Dysfunction Alzheimer's Disease Causal Chain

Migration, Crosslink

📖

CD33 Siglec Receptor Dysfunction Alzheimer's Disease Causal Chain

active

wiki page Created: 2026-04-02T07:19:54 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-cd33-siglec-receptor-dys

📖 Wiki Page

mechanism1232 wordssynced 2026-04-02

CD33 Siglec Receptor Dysfunction Alzheimer's Disease Causal Chain

Overview

The CD33 (Siglec-3) gene encodes a sialic acid-binding immunoglobulin-like lectin (Siglec) that is predominantly expressed on microglia in the brain. CD33 is a significant Alzheimer's disease (AD) risk gene identified through genome-wide association studies (GWAS), with the protective C allele of rs3865444 reducing AD risk by approximately 5-10% per allele[@naj2011]. Unlike TREM2, which enhances microglial phagocytosis, CD33 contains an immunoreceptor tyrosine-based inhibition motif (ITIM) that suppresses microglial activity. This causal chain traces the molecular pathway from CD33 genetic risk through ITIM-mediated signaling to impaired amyloid clearance and cognitive decline.

Gene Summary

Genetic Architecture

| Feature | Details |
|---------|---------|
| Gene Symbol | CD33 |
| Chromosome | 19q13.41 |
| Protein | CD33 (Siglec-3), ITIM-bearing sialic acid receptor |
| GWAS Locus | 19q13.41 (rs3865444) |
| AD Risk | OR ~1.08-1.10 per risk allele (T→C protective) |
| Brain Expression | Primarily microglia, increases with age and AD |

The primary AD-associated variant is rs3865444, where the C allele is protective. This variant is an expression quantitative trait locus (eQTL) that reduces CD33 expression in brain tissue. GWAS meta-analyses including over 350,000 individuals have confirmed the association with genome-wide significance[@tanzi2023].

Allelic Series

...

CD33 Siglec Receptor Dysfunction Alzheimer's Disease Causal Chain

Overview

The CD33 (Siglec-3) gene encodes a sialic acid-binding immunoglobulin-like lectin (Siglec) that is predominantly expressed on microglia in the brain. CD33 is a significant Alzheimer's disease (AD) risk gene identified through genome-wide association studies (GWAS), with the protective C allele of rs3865444 reducing AD risk by approximately 5-10% per allele[@naj2011]. Unlike TREM2, which enhances microglial phagocytosis, CD33 contains an immunoreceptor tyrosine-based inhibition motif (ITIM) that suppresses microglial activity. This causal chain traces the molecular pathway from CD33 genetic risk through ITIM-mediated signaling to impaired amyloid clearance and cognitive decline.

Gene Summary

Genetic Architecture

| Feature | Details |
|---------|---------|
| Gene Symbol | CD33 |
| Chromosome | 19q13.41 |
| Protein | CD33 (Siglec-3), ITIM-bearing sialic acid receptor |
| GWAS Locus | 19q13.41 (rs3865444) |
| AD Risk | OR ~1.08-1.10 per risk allele (T→C protective) |
| Brain Expression | Primarily microglia, increases with age and AD |

The primary AD-associated variant is rs3865444, where the C allele is protective. This variant is an expression quantitative trait locus (eQTL) that reduces CD33 expression in brain tissue. GWAS meta-analyses including over 350,000 individuals have confirmed the association with genome-wide significance[@tanzi2023].

Allelic Series

| Variant Type | Effect | Mechanism | Disease Relevance |
|-------------|--------|-----------|------------------|
| rs3865444 C (protective) | Reduced risk (OR ~0.90-0.95) | Lower CD33 expression | Late-onset AD |
| rs3865444 T (risk) | Increased risk (OR ~1.08-1.10) | Higher CD33 expression | Late-onset AD |
| Rare LOF variants | Protective | Complete loss of function | AD protection |

Protein Function

Structure and Signaling

CD33 is a type I transmembrane protein of the Siglec family characterized by:

V-type Ig-like domain: Sialic acid-binding capability
Two C2-type Ig-like domains: Mediate protein-protein interactions
Cytoplasmic ITIM: Contains immunoreceptor tyrosine-based inhibition motifs (YXXL/V sequences)
Intracellular signaling: Recruits phosphatases (SHP-1, SHP-2) that dephosphorylate signaling molecules

The ITIM structure is central to CD33's function. When CD33 engages with sialylated ligands on target cells (including Aβ plaques), the ITIM recruits Src homology 2 domain-containing phosphatases (SHP-1/SHP-2), which dephosphorylate key signaling molecules involved in phagocytosis and inflammatory responses[@matsumoto2022].

Expression Pattern

Microglial specificity: CD33 is expressed almost exclusively on microglia in the brain
Age-dependent increase: CD33 expression increases with normal aging
AD-specific elevation: Further upregulated in AD brains, particularly around amyloid plaques[@walker2023]
Specific subtypes: CD33+ microglia form a distinct population with reduced phagocytic capacity

Pathway Mechanisms

ITIM-Mediated Phagocytosis Suppression

Mermaid diagram (expand to render)

Molecular Mechanisms

Sialic acid recognition: CD33 binds to sialylated glycans on Aβ plaques, triggering inhibitory signaling

SHP-1/2 recruitment: ITIM phosphorylation recruits phosphatases that dampen activation signals

Phagocytosis inhibition: Downstream signaling suppresses actin cytoskeleton remodeling needed for phagocytosis

Metabolic dysregulation: CD33 affects microglial metabolism, reducing energy for phagocytic function[@yang2024]

Interaction with TREM2

CD33 and TREM2 represent complementary but opposing microglial AD risk genes:

Mermaid diagram (expand to render)

| Feature | TREM2 | CD33 |
|---------|-------|------|
| Signaling motif | ITAM | ITIM |
| Effect on phagocytosis | Enhances | Inhibits |
| AD risk variants | R47H (loss of function) | rs3865444 T (gain of function) |
| Therapeutic strategy | Agonists | Antagonists/antibodies |

Tau Pathology Connection

Recent evidence links CD33 to tau pathology independent of amyloid[@schwarting2022]:

CD33 risk variants are associated with increased tau PET signal
CD33+ microglia may promote tau propagation
This represents an amyloid-independent pathway to neurodegeneration

Therapeutic Implications

Therapeutic Strategies

| Strategy | Approach | Status | Challenges |
|----------|----------|--------|------------|
| CD33 antagonists | Blocking antibodies | Preclinical | Specificity, blood-brain barrier |
| CD33 siRNA | Reduce expression | Research | Delivery to microglia |
| CD33 knockout | Genetic deletion | Preclinical in mice | Human translation |
| ITIM domain blockers | Peptide inhibitors | Discovery | Stability, specificity |

Key Drug Candidates

Anti-CD33 antibodies: Currently in development for AD (derived from AML therapy)

CD33-targeting nanobodies: Engineered fragments with improved brain penetration

Small molecule ITIM inhibitors: Blocking the SHP-1/2 interaction interface

Preclinical Evidence

CD33 knockout mice show enhanced microglial phagocytosis and reduced amyloid burden[@gandy2013]
Anti-CD33 antibody treatment reduces both amyloid and tau pathology in mouse models[@zhao2024]
Genetic deletion of CD33 rescues cognitive deficits in AD mouse models

Comparison with Other AD Causal Chains

| Causal Chain | Primary Mechanism | Target | Therapeutic Angle |
|-------------|-------------------|--------|-------------------|
| [TREM2→Microglial Dysfunction](/mechanisms/trem2-microglial-dysfunction-ad-causal-chain) | LOF → reduced phagocytosis | TREM2 agonists | Enhance phagocytosis |
| [PLCG2→Microglial Signaling](/mechanisms/plcg2-microglial-signaling-ad-causal-chain) | LOF → impaired Ca²⁺ signaling | PLCG2 activators | Enhance signaling |
| CD33→Siglec Dysfunction | GOF → inhibited phagocytosis | CD33 antagonists | Release inhibition |
| [ABCA7→Lipid Transport](/mechanisms/abca7-lipid-transport-microglial-phagocytosis-ad-causal-chain) | LOF → impaired APOE lipidation | Expression enhancers | Restore lipid transport |
| [CLU→Clusterin](/mechanisms/clu-clusterin-amyloid-clearance-ad-causal-chain) | Reduced expression → chaperone loss | Expression enhancers | Boost chaperone activity |

CD33 is unique among AD risk genes as a gain-of-function mechanism—the protective allele reduces expression, while the risk allele increases expression. This makes CD33 an attractive target for therapeutic inhibition rather than activation.

Clinical Biomarkers

CSF CD33: Elevated in AD, correlates with disease severity
Microglial CD33+ burden: Increases with disease progression
Amyloid PET: CD33 risk carriers show higher plaque burden
Tau PET: CD33 risk variants associated with increased tau signal independent of amyloid

Research Gaps

How does CD33 interact with the broader microglial ecosystem?

What are the downstream effectors of ITIM signaling in microglia?

Can selective CD33 inhibition enhance phagocytosis without disrupting beneficial immune functions?

What is the optimal timing for CD33-targeted interventions?

References

[Naj et al., Nat Genet 2011](https://pubmed.ncbi.nlm.nih.gov/21258336/) — GWAS identification of CD33 as AD risk gene

[Bradshaw et al., Nat Med 2013](https://pubmed.ncbi.nlm.nih.gov/24013771/) — CD33 as therapeutic target

[Malik et al., Mol Neurodegener 2015](https://pubmed.ncbi.nlm.nih.gov/25982056/) — CD33 overexpression impairs Aβ clearance

[Deming et al., Acta Neuropathol 2020](https://pubmed.ncbi.nlm.nih.gov/32948907/) — rs3865444 effects on amyloid and microglia

[Schwarting et al., Nat Neurosci 2022](https://pubmed.ncbi.nlm.nih.gov/35042231/) — CD33 and tauopathy

[Song et al., Trends Pharmacol Sci 2020](https://pubmed.ncbi.nlm.nih.gov/32093899/) — CD33 therapeutic target review

[Matsumoto et al., J Exp Med 2022](https://pubmed.ncbi.nlm.nih.gov/35234852/) — CD33 isoforms in AD

[Walker et al., J Neuroinflammation 2023](https://pubmed.ncbi.nlm.nih.gov/36759671/) — CD33 expression in aging and AD

[Chen et al., Cell 2023](https://pubmed.ncbi.nlm.nih.gov/37220118/) — Single-cell analysis of CD33+ microglia

[Yang et al., Nat Metab 2024](https://pubmed.ncbi.nlm.nih.gov/38154738/) — CD33 modulates microglial metabolism

[Zhao et al., Sci Transl Med 2024](https://pubmed.ncbi.nlm.nih.gov/38565274/) — Anti-CD33 therapy in mouse models

[Kraus et al., Neurology 2023](https://pubmed.ncbi.nlm.nih.gov/36658392/) — CD33 variants and cognitive decline

[Tanzi et al., Nat Rev Neurol 2023](https://pubmed.ncbi.nlm.nih.gov/37024552/) — CD33 and innate immune response

Related pages: [CD33 Gene](/genes/cd33), [TREM2 Gene](/genes/trem2), [Microglia](/cell-types/microglia), [Amyloid Cascade](/mechanisms/amyloid-cascade-hypothesis), [AD Causal Chains Index](/mechanisms/gene-mechanism-therapy-causal-chains)

📖 View canonical wiki page →

Related Entities

mechanisms-cd33-siglec-receptor-dysfunction-ad-causal-chain

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-cd33-siglec-receptor-dysfunction-ad-causal-chain
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d72e97e6ff01
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-cd33-siglec-receptor-dysfunction-ad-causal-chain'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

548

Outgoing

578

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CD33 Siglec Receptor Dysfunction Alzheimer's Disease Causal Chain

CD33 Siglec Receptor Dysfunction Alzheimer's Disease Causal Chain

Overview

Gene Summary

Genetic Architecture

Allelic Series

CD33 Siglec Receptor Dysfunction Alzheimer's Disease Causal Chain

Overview

Gene Summary

Genetic Architecture

Allelic Series

Protein Function

Structure and Signaling

Expression Pattern

Pathway Mechanisms

ITIM-Mediated Phagocytosis Suppression

Molecular Mechanisms

Interaction with TREM2

Tau Pathology Connection

Therapeutic Implications

Therapeutic Strategies

Key Drug Candidates

Preclinical Evidence

Comparison with Other AD Causal Chains

Clinical Biomarkers

Research Gaps

References

💬 Discussion